Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?
Published: | Updated:
In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.
Sanoj Punnen, MD, MAS
Advertisement
Articles by Sanoj Punnen, MD, MAS
Advertisement
Latest Updated Articles
Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?Published: June 19th 2019 | Updated: November 11th 2020
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Accelerated Approval to Zongertinib in HER2+ NSCLC
2
Enzalutamide/Radium-223 Extends Survival in mCRPC
3
Enfortumab Vedotin Combo Boosts MIBC Survival Outcomes in EV-304 Trial
4
Overcoming Challenges to Access for Proton-Based Radiotherapy in OPSCC
5